[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552511":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":57,"collaborators":24,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":24,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":39,"whyStopped":24,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment 1","EXPERIMENTAL","Phase 1",[13],"Drug: Trelegy or Anoro",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment 2","Phase 2",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Trelegy or Anoro","Both drugs delivered via Ellipta device and blinded package appearance",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Kittipong Maneechotesuwan, MD,PhD","Siriraj Hospital","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"kittipong maneechotesuwan, MD, PhD.","CONTACT","0894996858","kittipong.man@mahidol.ac.th",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":24,"geoPoint":24,"contacts":45},"Division of Respiratory Disease and TB, Siriraj Hospital","RECRUITING","Bangkoknoi","BKK","10700","Thailand","TH",[46,51,55],{"name":47,"role":33,"phone":48,"phoneExt":49,"email":50},"Kittipong - Maneechotesuwan, MD., PhD.","06624197757","15","sikmn@mahidol.ac.th",{"name":52,"role":33,"phone":53,"phoneExt":24,"email":54},"Adisak - Wongkajornsilp, MD., Ph.D.","06624198573","siawj@mahidol.ac.th",{"name":56,"role":29,"phone":24,"phoneExt":24,"email":24},"Kittipong Maneechotesuwan, MD., PhD.",{"type":29,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Kittipong Maneechotesuwan","Professor Dr.","100552511","phase-3-the-efficacy-of-fluticasone-furoatevilanterolumeclidinium-compared-with-vilanterolumeclidinium-in-reducing-air-trapping-and-airway-and-blood-cytokine-levels-in-copd-100552511",false,"NCT06474039","The Efficacy of Fluticasone Furoate\u002FVilanterol\u002FUmeclidinium Compared With Vilanterol\u002FUmeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD","Inclusion Criteria:\n\n* Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.\n* Patients with COPD GOLD B are previously treated with either LAMA or LAMA\u002FLABA or short-acting bronchodilators\n* Patients who are able to provide informed consent.\n\nExclusion Criteria:\n\n* \\- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.\n* Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids\n* Being treated with triple therapy (ICS\u002FLABA\u002FLAMA)\n* Being in terminally ill conditions","ALL","40 Years","80 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","This study aims to demonstrate the effects of triple therapy (ICS\u002FLABA\u002FLAMA) and dual bronchodilators (LAMA\u002FLABA) on air trapping in the lungs' COPD patients and inflammatory mediators",[77],"COPD","2025-05-01",{"date":80,"type":81},"2025-05-06","ACTUAL",{"date":83,"type":81},"2024-10-01",{"date":85,"type":71},"2026-12",{"name":5,"class":6},1]